| 胃肠道间质瘤肝转移治疗进展 |
| |
| 引用本文： | 王立平,梁小波. 胃肠道间质瘤肝转移治疗进展[J]. 国外医学(肿瘤学分册), 2007, 0(1) |
| |
| 作者姓名： | 王立平 梁小波 |
| |
| 作者单位： | 山西医科大学第二临床医学院普外科，山西医科大学第二临床医学院普外科 |
| |
| 摘 要： | 胃肠道问质瘤(GIST)常见的转移器官是肝脏。GIST肝转移以外科治疗为主,术后3年、5年生存率分别可达58%和30%以上。生物靶向制剂治疗以伊马替尼为代表,但有部分患者耐药。其他靶向治疗药物如SU11248、RAD001、AMG706正在临床试验中,以解决伊马替尼耐药问题。伊马替尼新辅助和辅助治疗试验仍在进行中。介入治疗对GIST肝转移为有效的姑息疗法,肝移植也有一定效果。总之,外科联合生物治疗有望成为GIST肝转移个体化治疗的突破。
|
| 关 键 词： | 胃肠肿瘤 间质瘤 肝肿瘤 治疗 |
Advances in the therapy of hepatic metastases from gastrointestinal stromal tumors |
| |
| WANG Li- ping. Advances in the therapy of hepatic metastases from gastrointestinal stromal tumors[J]. Foreign Medical Sciences (Cancer Section), 2007, 0(1) |
| |
| Authors: | WANG Li- ping |
| |
| Affiliation: | WANG Li- ping Department of General Surgery,the Second Clinical Medicine College of Shanxi Medical University,Taiyuan 030001,China |
| |
| Abstract: | Liver is a frequent metastatic organ of gastrointestinal stromal tumors (GIST).The major treatment for hepatic metastases from GIST is surgery by which the overall survival rates at 3 and 5 years are over 58% and 30%,respectively.Imatinib is used as a major targeting preparation in biotherapy.There is still some patients with imatinib resistance.Other targeting preparation drugs,such as SU11248,RADO01 and AMG706 are being evaluated as treatment options for patients who are not controlled by imatinib alone.Imatinib in the neoadjuvant and adjuvant settings are currently conducted.In addition interventional therapies are used as alleviative treatments.Liver transplantation also get certain effect.Ultimately,operation combined with biotherapy may have a breakthrough in individualized treatment about hepatic metastases from GIST. |
| |
| Keywords: | Gastrointestinal neoplasms Stromal tumors Liver neoplasms Therapy |
| 本文献已被 CNKI 等数据库收录！ |
|
